A clinical trial aims to prevent kidney damage using isatuximab in a condition called Monoclonal Gammopathy of Renal Signifcance.
Monoclonal Gammopathies (MG) are disorders characterized by the production of abnormal immunoglobulins, also known as monoclonal proteins, that do not meet the criteria for multiple myeloma. Recently a new entity has been identified in this group, the Monoclonal Gammopathy of Renal Significance (MGRS), in which the monoclonal proteins accumulate on the kidney and cause kidney damage without meeting the diagnostic criteria for multiple myeloma. Currently, the reason for this protein accumulation is unknown.
Even if a Monoclonal Gammopathy does not initially require therapy from the standpoint of the tumor, the current guidelines agree that treatment should be considered obligatory and should begin as soon as possible when there is kidney damage.
Currently, the treatment options for MGRS are limited, but during the last ten years, we have seen a revolution in the treatment of multiple myeloma and the use of anti-CD38 treatments. Understanding the effect of isatuximab, an anti-CD38 monoclonal antibody, in MGRS can help us significantly improve the treatment opportunities of patients with this disease.
This study is evaluating the effect of isatuximab (Sarclisa), an anti-CD38 monoclonal antibody, on kidney outcomes in patients with monoclonal gammopathy of renal significance (MGRS) and determine any abnormalities that could cause the production of abnormal proteins that collect in the kidney (renal parenchyma), and cause kidney damage.
The study will determine:
Patients who can join the study include patients with:
For more information about the inclusion/exclusion criteria, click here.
The study is open at Massachusetts General Hospital (Renal Associates Clinic), and Columbia University Irving Medical Center.
about the author
Arturo Hurtado
Arturo Hurtado is an International Medical Graduate who Joined HealthTree in 2020 as part of The Patient Experience team. He helps patients understand their disease panorama and navigate their myeloma through the tools and resources that HealthTree provides. He is an enthusiastic photographer, tech nerd, and aspiring food explorer who loves to travel and find new exciting experiences.
Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.